Skip to Content

Tritanrix HepB

Active Substance: diphtheria toxoid / hepatitis B recombinant surface antigen / Bordetella pertussis (inactivated) / tetanus toxoid
Common Name: diphtheria, tetanus, pertussis (whole cell) and hepatitis-B (rDNA) vaccine (adsorbed)
ATC Code: J07CA05
Marketing Authorisation Holder: GlaxoSmithKline Biologicals S.A.
Active Substance: diphtheria toxoid / hepatitis B recombinant surface antigen / Bordetella pertussis (inactivated) / tetanus toxoid
Status: Withdrawn
Authorisation Date: 1996-07-19
Therapeutic Area: Hepatitis B Diphtheria Whooping Cough Immunization Tetanus
Pharmacotherapeutic Group: Vaccines

Therapeutic Indication

Tritanrix HepB is indicated for active immunisation against diphtheria, tetanus, pertussis and hepatitis B (HBV) in infants from six weeks onwards (see section 4.2).

The marketing authorisation for Tritanrix HepB has lapsed because it ceased to be marketed in the European Union more than three years ago and an exemption granted by the European Commission has expired

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide